A cohort study of combined Chinese and Western medicine in the treatment of chronic kidney disease

Early Phase 1

• Conditions: chronic kidney disease; GB61.Z

• Registration Number: ITMCTR2024000108
• Lead Sponsor: Affiliated Hospital of Changchun University of Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 July 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Meet the diagnostic criteria for CKD in the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines (2012) of the International Kidney Disease Organization. 2. = 10 years. 3. Be able to sign the informed consent form.

Exclusion Criteria

1. Diagnosis of one of the following diseases: polycystic kidney, human immunodeficiency virus infection, cirrhosis of the liver, multiple myeloma. 2. Conditions deemed severe or unsuitable for participation in the study by the attending physician. 3. Concurrently participate in other interventional clinical trials. 4. Unable to cooperate in completing the assessment of cognitive function or have comorbidities that interfere with the assessment of cognitive function such as intracranial tumors, traumatic brain injuries, visualization, and hearing pathology. 5. CKD caused by systemic inflammatory diseases or autoimmune diseases such as lupus erythematosus. 6. Pregnant or breastfeeding women. 7. Patients with hereditary renal disease.

Study & Design

• Study Type: Observational study
• Study Design: Not specified